Phio Pharmaceuticals (PHIO) EBIT Margin (2016 - 2019)
Historic EBIT Margin for Phio Pharmaceuticals (PHIO) over the last 8 years, with Q1 2019 value amounting to 10219.05%.
- Phio Pharmaceuticals' EBIT Margin fell 4842700.0% to 10219.05% in Q1 2019 from the same period last year, while for Dec 2019 it was 42795.24%, marking a year-over-year decrease of 374590100.0%. This contributed to the annual value of 42795.24% for FY2019, which is 374590100.0% down from last year.
- Per Phio Pharmaceuticals' latest filing, its EBIT Margin stood at 10219.05% for Q1 2019, which was down 4842700.0% from 2617.54% recorded in Q3 2018.
- Phio Pharmaceuticals' EBIT Margin's 5-year high stood at 2617.54% during Q3 2018, with a 5-year trough of 24611.11% in Q2 2016.
- Moreover, its 5-year median value for EBIT Margin was 9976.92% (2018), whereas its average is 11855.58%.
- As far as peak fluctuations go, Phio Pharmaceuticals' EBIT Margin crashed by -137852900bps in 2016, and later plummeted by -4842700bps in 2019.
- Quarter analysis of 5 years shows Phio Pharmaceuticals' EBIT Margin stood at 8664.71% in 2015, then plummeted by -184bps to 24611.11% in 2016, then surged by 46bps to 13273.33% in 2017, then skyrocketed by 80bps to 2617.54% in 2018, then crashed by -290bps to 10219.05% in 2019.
- Its EBIT Margin stands at 10219.05% for Q1 2019, versus 2617.54% for Q3 2018 and 3274.14% for Q2 2018.